Shimane Toshikazu, Mori Tomoaki, Ono Tomohiro, Kaburagi Aya, Monden Tetsuya, Furuya Ayako, Kamakazu Kiyoaki, Kobayashi Sei, Sanbe Takeyuki, Suzaki Harumi
Dept. of Otorhinolaryngology, Showa University, Fujigaoka Hospital.
Gan To Kagaku Ryoho. 2010 Feb;37(2):241-4.
Laryngeal cancer occurs more frequently in head and neck cancers, so there are a number of reports regarding the treatment results,wherein the therapeutic strategy and results are stable to some extent. However, due to the spread of chemoradiotherapy, there are differences in the larynx preservation rates for T2 and T3 cases, depending on the facility. Our department has been administering chemoradiotherapy for advanced cancer based on the perspective of conserving the organ and the function. We herein report our examination of 20 laryngeal cancer cases receiving concomitant therapy with S-1, Nedaplatin, and radiation (hereinafter, referred to as SN therapy) in our department from April 2005 to December 2008. The resulting complete response (CR) rate for the SN therapy was 82.4%, excluding T4 cases. Due to their refusal of surgery, 2 of 3 cases in which the SN therapy had been administered for T4 cases receiving SN therapy showed CR, wherein the CR rate in all cases after the SN therapy was 80. 0%. The larynx preservation rate after the SN therapy was 94.1%.
喉癌在头颈癌中更为常见，因此有许多关于治疗结果的报告，其中治疗策略和结果在一定程度上是稳定的。然而，由于放化疗的推广，根据医疗机构的不同，T2和T3病例的喉保留率存在差异。我们科室一直从保留器官和功能的角度对晚期癌症进行放化疗。在此，我们报告2005年4月至2008年12月在我们科室接受S-1、奈达铂和放疗联合治疗（以下简称SN疗法）的20例喉癌病例的研究情况。排除T4病例后，SN疗法的完全缓解（CR）率为82.4%。在接受SN疗法的3例T4病例中，有2例因拒绝手术而显示CR，其中SN疗法后所有病例的CR率为80.0%。SN疗法后的喉保留率为94.1%。
